EXEL Crosses Above Key Moving Average Level Thursday, April 11, 11:34 AM ET, by Market News Video Staff In trading on Thursday, shares of Exelixis Inc (EXEL) crossed above their 200 day moving ...
Land INFI Even Cheaper Than Its Secondary? Monday, April 15, 3:35 PM ET, by Market News Video Staff Looking back to 4 days ago, Infinity Pharmaceuticals Inc (INFI) priced a 10,000,000 share secondary ...
Oversold Conditions For Dendreon Corp (DNDN) Thursday, April 18, 4:29 PM ET, by Market News Video Staff Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...
Land ITMN 10.0% Cheaper Than Its Secondary? Monday, April 22, 2:38 PM ET, by Market News Video Staff Looking back to 96 days ago, InterMune Inc. (ITMN) priced a 13,500,000 share secondary stock ...
In trading on Friday, shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) crossed below their 200 day moving average of $7.74, changing hands as low as $7.68 per share. Neurocrine Biosciences, Inc. shares are currently trading down about 3% on the day. The chart below shows the one year performance of NBIX shares, versus its 200 day moving average:
Looking at the chart above, NBIX's low point in its 52 week range is $5.42 per share, with $9.98 as the 52 week high point — that compares with a last trade of $7.70.
According to the ETF Finder at ETF Channel, NBIX makes up 1.06% of the SPDR S&P Biotech ETF (AMEX:XBI) which is trading higher by about 0.8% on the day Friday.
This Article's Word Cloud:AccordingAverageBelowBiosciencesBiotechETFsFinderFridayLookingManageManagementMovingNBIXNeurocrineOfferPortfolioRiskSpecialStartStocksTheiraboutaboveaveragebelowchangingchartcontaincrossedcurrentlydownhandshighhighermovingotherperformancepointrangeraquoriskssharesharesstockstradetradingtrialweekwhatwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.